title: Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.
abstract: A significant percentage of human immunodeficiency virus type 1 (HIV-1)-infected persons treated with highly active antiretroviral therapy (HAART) will develop plasma HIV-1-specific virion RNA levels <50 copies/mL. HIV-1-infected persons receiving virally suppressive HAART were studied with a viral outgrowth assay of the patients' peripheral blood mononuclear cells (PBMC), and a quantitative polymerase chain reaction assay was used to analyze HIV-1 2-long terminal repeat (2-LTR) circular DNA in PBMC, which indicates new HIV-1 infections of cells in vivo. Viral outgrowth in vitro correlated inversely with the level of peripheral blood CD4(+) T lymphocytes. Detection and quantitation of 2-LTR circular DNA correlated strongly with viral outgrowth patterns and inversely with CD4(+) T lymphocyte counts. Relevant subgroups of HIV-1-infected subjects on suppressive HAART with residual viral disease and reservoirs can now be stratified.
authors.affiliation: Dorrance H. Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
authors.forename: G
authors.initials: G
authors.lastname: Dornadula
authors.forename: G
authors.initials: G
authors.lastname: Nunnari
authors.forename: M
authors.initials: M
authors.lastname: Vanella
authors.forename: J
authors.initials: J
authors.lastname: Roman
authors.forename: T
authors.initials: T
authors.lastname: Babinchak
authors.forename: J
authors.initials: J
authors.lastname: DeSimone
authors.forename: J
authors.initials: J
authors.lastname: Stern
authors.forename: M
authors.initials: M
authors.lastname: Braffman
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: R J
authors.initials: RJ
authors.lastname: Pomerantz
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000821:virology; D015331:Cohort Studies; D018076:DNA, Complementary / Q000032:analysis; D004279:DNA, Viral / Q000032:analysis*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000821:virology*; D016325:HIV Long Terminal Repeat / Q000235:genetics; D015497:HIV-1 / Q000235:genetics* / Q000472:pathogenicity; D006801:Humans; D008297:Male; D011533:Proviruses / Q000235:genetics*; D013997:Time Factors; D014779:Virus Replication
chemical_list: D019380:Anti-HIV Agents; D018076:DNA, Complementary; D004279:DNA, Viral